Blockade of IL-17A by ixekizumab appears to benefit patients with complex multi-domain psoriatic disease including nail psoriasis. Speaking at the virtual EADV 29th Congress, Professor Kristian Reich from Germany presented a post hoc analysis of the SPIRIT-H2H study which compared ixekizumab versus adalimumab in adults with active psoriatic arthritis (PsA) and moderate-severe psoriasis. The original ...
Ixekizumab outperforms adalimumab in nail psoriasis
By Mardi Chapman
4 Nov 2020